Sartorius Ag · XETR:SRT
Sartorius — H1 2026 Earnings Presentation
20 slides from Sartorius's earnings presentation, Jul 23, 2026
Slide 1: Investor Conference Call H1 2026 Results
Investor Conference Call H1 2026 Results Michael Grosse, Florian Funck, René Fáber Sartorius | Sartorius Stedim Biotech | July 23, 2026
Slide 2: Agenda
Agenda Sartorius Group H1 2026 results | FY 2026 outlook Sartorius Stedim Biotech Group H1 2026 results | FY 2026 outlook Questions & Answers 2
Slide 3: H1 confirms robust market fundamentals
Sartorius Group H1 confirms robust market fundamentals ▪ Operational sales growth1 of 7.7%, with slightly >9% consumables and around 2% equipment growth ▪ Robust topline drives ul. EBITDA margin up to 30.3% ▪ Refunds for US tariffs received at the end of Q2; intended customer compensation for tariff
Slide 4: Enabling innovative therapies through advanced manufacturing and AI-driven, digital workflows
Sartorius Group Enabling innovative therapies through advanced manufacturing and AI-driven, digital workflows Pionic Modules Ambr 250 HT Cubis III Incucyte Quad & Cross Cell Therapies Vessel Premium Balance Live cell analysis Bioreactor for culturing Next-generation weighing Continuous expansion of
Slide 5: Robust underlying sales performance; non-operational headwind from tariff-related effects
Sartorius Group Robust underlying sales performance; non-operational headwind from tariff-related effects Sartorius Group Bioprocess Solutions Lab Products & Services Sales revenue | € in millions Sales revenue | € in millions Sales revenue | € in millions +7.7%1 | +6.2% cc | +2.5% +8.3%1 | +6.7% cc
Slide 6: All regions contribute positively to business development
Sartorius Group All regions contribute positively to business development EMEA Americas Asia | Pacific Sales revenue | € in millions Sales revenue | € in millions Sales revenue | € in millions 7.2% cc | +7.2% +5.6%1 | +1.2% cc | -4.8% +12.1% cc | +5.4% 732 784 638 608 397 419 H1 2025 H1 2026 H1 2025
Slide 7: Robust topline drives earnings and margins up
Sartorius Group Robust topline drives earnings and margins up Sartorius Group Bioprocess Solutions Lab Products & Services Ul. EBITDA & margin | Ul. EBITDA & margin | Ul. EBITDA & margin | € in millions € in millions € in millions +3.9% +5.2% -4.0% 29.8% 30.3% 31.6% 32.3% 527 548 453 477 22.3% 21.2%
Slide 8: Continued sound cash flow development
Sartorius Group Continued sound cash flow development Sartorius Group H1 2025 H1 2026 in % € in millions Underlying net profit1,2 169 172 +2.0 ▪ Underlying net profit mainly reflects improved operating profit Underlying EPS (ord.) 2.44 2.49 +2.0 ▪ Strong increase in net profit driven by lower extrao
Slide 9: Deleveraging progresses as expected; unchanged commitment to investment-grade rating
Sartorius Group Deleveraging progresses as expected; unchanged commitment to investment-grade rating Key financial indicators Net debt and net debt to underlying EBITDA 6.0 Sartorius Group Dec. 31, Jun. 30, 5,000 € in millions unless otherwise specified 2025 2026 5.0 4,000 4.0 Equity ratio in % 39.8
Slide 10: FY 2026 guidance confirmed
Sartorius Group FY 2026 guidance confirmed FY 2026 guidance Sales revenue growth1 Ul. EBITDA margin Operational performance excl. effects from tariff-related customer compensation ~5% to ~9% Sartorius Group Slightly > 30% (thereof ~0.3pp MATTEK) ▪ Remains robust and in line with initial expectations
Slide 11: Agenda
Agenda Sartorius Group H1 2026 results | FY 2026 outlook Sartorius Stedim Biotech Group H1 2026 results | FY 2026 outlook Questions & Answers 11
Slide 12: Robust underlying sales performance; non-operational headwind from tariff-related effects; improved profitability
Sartorius Stedim Biotech Group Robust underlying sales performance; non-operational headwind from tariff-related effects; improved profitability Sales revenue | € in millions Ul. EBITDA & margin | € in millions 8.0%1 | +6.4% cc | +2.5% +3.7% 1,527 31.4% 1,490 31.0% 462 479 H1 2025 H1 2026 H1 2025 H1
Slide 13: All regions contribute positively to business development
Sartorius Stedim Biotech Group All regions contribute positively to business development EMEA Americas Asia | Pacific Sales revenue | € in millions Sales revenue | € in millions Sales revenue | € in millions +7.7% cc | +7.6% +5.4%1 | +0.8% cc | -5.4% +12.5% cc | +5.9% 672 625 541 512 323 342 H1 2025
Slide 14: Continued sound cash flow development
Sartorius Stedim Biotech Group Continued sound cash flow development Sartorius Stedim Biotech H1 2025 H1 2026 in % € in millions ▪ Underlying net profit mainly reflects improved Underlying net profit1,2 228 235 +3.1 operating profit Underlying EPS 2.34 2.42 +3.1 ▪ Strong increase in net profit drive
Slide 15: Strong balance sheet; deleveraging ongoing
Sartorius Stedim Biotech Group Strong balance sheet; deleveraging ongoing Key financial indicators Net debt and net debt to underlying EBITDA 4,000 6.0 Sartorius Stedim Biotech Dec. 31, Jun. 30, 5.0 € in millions unless otherwise specified 2025 2026 3,000 4.0 Equity ratio in % 51.7 53.6 2,000 3.0 2.
Slide 16: FY 2026 guidance confirmed
Sartorius Stedim Biotech Group FY 2026 guidance confirmed Operational performance excl. effects from tariff-related FY 2026 guidance Sales revenue growth1 Ul. EBITDA margin customer compensation ▪ Remains robust and largely in line with initial expectations Sartorius Stedim and current trading Biote
Slide 17: Questions & Answers
17 Questions & Answers SARTORI
Slide 18: Contacts and Financial calendar
Sartorius Group Contacts and Financial calendar Sven Köpsel September 1, 2026 September 21, 2026 Head of Corporate Communications & IR Commerzbank and ODDO BHF RBC Life Science Conf., virtual Corporate Conf., Frankfurt September 22, 2026 +49.551.308.9429 September 2, 2026 Berenberg and Goldman Sachs
Slide 19: Disclaimer
Disclaimer This presentation contains statements concerning the future performance of the Sartorius and the Sartorius Stedim Biotech Groups. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee tha
Slide 20: Simplifying Progress
Simplifying Progress